Hua Medicine
Hua Medicine, officially known as Hua Medicine (Shanghai) Co., Ltd., is a pioneering biopharmaceutical company headquartered in Shanghai, China. Founded in 2016, the company focuses on the development of innovative therapies for diabetes and related metabolic disorders, positioning itself at the forefront of the healthcare industry. With a commitment to advancing diabetes treatment, Hua Medicine has developed unique products, including its lead candidate, HM15136, which aims to improve glycaemic control. The company has achieved significant milestones, including successful clinical trials that underscore its potential to transform diabetes management. Recognised for its cutting-edge research and development capabilities, Hua Medicine is rapidly establishing itself as a key player in the global biopharmaceutical market, dedicated to enhancing patient outcomes through innovative solutions.
DitchCarbon Score
How does Hua Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hua Medicine's score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hua Medicine's reported carbon emissions
In 2023, Hua Medicine reported total carbon emissions of approximately 43,574,700 kg CO2e, comprising 19,201,000 kg CO2e from Scope 1 and 416,546,000 kg CO2e from Scope 2 emissions. This marks a significant increase in emissions compared to 2022, when the company recorded total emissions of about 329,500 kg CO2e, with Scope 1 emissions at approximately 17,170 kg CO2e and Scope 2 emissions at about 312,330 kg CO2e. Hua Medicine has set ambitious reduction targets, aiming for a 30% reduction in both Scope 1 and Scope 2 emissions by 2030. This commitment reflects the company's proactive approach to adopting low-carbon emission reduction technologies, which is expected to mitigate future operational costs associated with high-emission activities. The emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Hua Medicine (Shanghai) Ltd. The company has not disclosed any Scope 3 emissions data, which is often a significant component of total corporate emissions. Overall, Hua Medicine's climate commitments and reduction initiatives demonstrate a clear focus on sustainability and environmental responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 15,190 | 00,000.00 | 00,000,000 |
| Scope 2 | 413,090 | 000,000.00 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hua Medicine is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
